Ftse Mib
33.973,54
1,02%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.524,14
-0,74%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Hoth Therapeutics Inc (HOTH) Hoth Therapeutics Inc (HOTH) Notizie

Hoth Therapeutics Inc

HOTH
1,17
-0,04 (-3,31%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 00:07:16
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
01/5/202414:00PRNUSHoth Therapeutics to Attend EF Hutton Annual Global..
27/3/202419:00PRNUSHoth Therapeutics Announces Exercise of Warrants for $4.2..
27/3/202413:27PRNUSHoth Therapeutics' Wholly Owned Subsidiary Merveille.ai,..
19/3/202413:21PRNUSHoth Therapeutics Announces Positive Data In Completed Study..
29/2/202414:38PRNUSHoth Therapeutics Retains Venable LLP to Expand Its Patent..
26/2/202414:11PRNUSHoth Therapeutics Engages Altasciences to Perform Key Study..
13/2/202417:45PRNUSHoth Therapeutics to Attend BIO CEO and Investor Conference,..
18/1/202414:20PRNUSHoth Therapeutics Announces it Received FDA Approval to..
09/1/202421:03EDGAR2Form 8-K - Current report
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202314:21PRNUSHoth Therapeutics Announces Expansion of FDA Cleared..
05/12/202314:33PRNUSHoth Therapeutics Announces it Has Successfully Completed..
14/11/202314:37PRNUSHoth Therapeutics Announces Successful Completion of Pre-IND..
13/11/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/11/202314:00PRNUSHoth Therapeutics to Present at NobleCon's 19th Annual..
05/10/202316:03PRNUSHoth Therapeutics Announces Merveille.ai Artificial..
05/10/202314:15EDGAR2Form 8-K - Current report
02/10/202314:33PRNUSFDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT,..
15/9/202322:15EDGAR2Form 8-K - Current report
15/9/202320:38PRNUSHoth Therapeutics Announces Closing of $2.89 Million..
14/9/202323:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/9/202319:43PRNUSHoth Therapeutics Announces $2.89 Million Registered Direct..
13/9/202314:16PRNUSHoth Therapeutics Announces Positive Results Killing Cancer..
11/9/202316:04PRNUSHoth Therapeutics Announces FDA Accepts Pre-Investigational..
06/9/202314:12PRNUSHoth Therapeutics Announces Positive Final Results from..
21/8/202323:10EDGAR2Form 8-K - Current report
21/8/202323:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202314:13PRNUSHoth Therapeutics Announces Positive Preclinical End Point..
25/7/202314:12PRNUSHoth Therapeutics Announces Major Milestone of First Patient..
19/7/202314:02PRNUSHoth Therapeutics Receives Protocol Approval for HT-001..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202314:12PRNUSHoth Therapeutics Announces IRB Approval for FDA Cleared..
06/6/202314:02PRNUSHoth Therapeutics Announces Positive Preclinical Results of..
12/5/202314:38PRNUSHoth Therapeutics and Algorithm Sciences Terminate Letter of..
Apertura: 1,21 Min: 1,17 Max: 1,23
Chiusura: 1,21

La tua Cronologia

NASDAQ
HOTH
Hoth Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network